Previous 10 | Next 10 |
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Revance Therapeutics To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - December 13, 2021) - Faruqi & Faruqi, LLP, a leading national securi...
Revance Therapeutics (RVNC +10.7%) shares are on the rise after Aubrey Rankin, President of Innovation & Tech, purchased 30,000 company shares, worth ~$430K. The shares were purchased at $14.33 - $14.50 in a transaction dated Dec 03, 2021. Form 4 A look at Revance Therapeutics' ownership ...
Shares of Revance Therapeutics (RVNC +7.2%) are trading up today following CEO Mark Foley's purchase of 40K shares. Foley acquired the shares yesterday at an average price of $12.90 for a total purchase price of $515,924. He now owns 110,913 shares individually and an additional 769,065 share...
- Two presentations highlighting data on DaxibotulinumtoxinA for Injection, including one oral presentation showcasing new data on clinical immunogenicity from the SAKURA Phase 3 program, and one abstract on injection technique for midface volumization with hyaluronic acid based fille...
Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company’s Chief Executive Officer, Mark Foley, and Chief Financial Officer, Tobin Schilke, will participate in a fireside chat at...
New York, New York--(Newsfile Corp. - November 14, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Revance Therapeutics, Inc. ("Revance Therapeutics" or the "Company") (NASDAQ: RVNC). If you suffered losses exceeding $50,000...
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Revance Therapeutics To Contact Him Directly To Discuss Their Options NEW YORK - ( NewMediaWire ) - November 12, 2021 - Faruqi & Faruqi, LLP, a leading national securities...
Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company will participate in the Stifel 2021 Virtual Healthcare Conference, a fully virtual management access conference, taking place No...
Revance Therapeutics, Inc. (RVNC) Q3 2021 Earnings Conference Call November 9, 2021 04:30 PM ET Company Participants Jessica Serra - IR Mark Foley - CEO Dustin Sjuts - President Toby Schilke - CFO Roman Rubio - SVP, Clinical Development Conference Call Participants Ken Cacciatore - Cowen and ...
Image source: The Motley Fool. Revance Therapeutics Inc (NASDAQ: RVNC) Q3 2021 Earnings Call Nov 9, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Revance Therapeutics Inc (RVNC) Q3 2021 Earnings Call Transcript
News, Short Squeeze, Breakout and More Instantly...
Revance Therapeutics Inc. Company Name:
RVNC Stock Symbol:
NASDAQ Market:
Revance Therapeutics Inc. Website:
- Total net product revenue (DAXXIFY® and RHA® Collection) of $51.7 million, a YoY increase of 13%. - DAXXIFY® net revenue of $22.1 million, after a reduction of $2.0 million related to a consumer coupon program. - Toxin market share increased from 3.0% in Q4’23 to 3...
Conference Call Scheduled for Thursday, May 9, 2024 at 4:30 p.m. ET. Revance Therapeutics, Inc. (NASDAQ: RVNC), today announced that the company will release first quarter 2024 financial results on Thursday, May 9, 2024, after the close of market. Revance will host a corresponding confe...